Saguaro Biosciences, a Quebec City, Canada-based developer of live cell reagents for AI-enhanced discoveries, raised $3M in Seed funding.
The round was led by AQC Capital and Anges Québec, with participation from Martin Leblanc, Co-Founder and Vice-Chairman of CellCarta Biosciences, alongside investments from Investissement Quebec and Ville de Québec.
The company intends to use the funds to drive the commercial expansion of ChromaLive™, its reagent platform, which enables time-sensitive imaging and AI-enabled analysis of cells.
Led by CEO Louis Turcotte, Saguaro Biosciences is dedicated to advancing life sciences with innovative reagents for AI-enabled cell analysis. With its flagship product, ChromaLive™, the company provides researchers around the world with tools to demystify cell biology, thereby accelerating the path to new discoveries and therapies. It is already adopted by major pharmaceutical companies.
Commenting on the news, Louis Turcotte said: “This funding will not only accelerate our technology’s adoption but also allow the expansion of our portfolio, paving the way for transformative applications that contribute to building the future of human health.”
FinSMEs
04/06/2024